ProADM Biomarker Multimarker Strategy for Post-MI Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and risk stratifying adverse events in post-myocardial infarction patients are unreliable, particularly in clinical decision-making for heart failure and death, as they rely heavily on natriuretic proteins like BNP and NTproBNP, which have limitations in predicting high-risk patients.
Innovation Solution
A method involving the determination of pro-adrenomedullin (proADM) or its fragments, such as mid-regional proADM (MR-proADM), in combination with other markers like BNP, NTproBNP, inflammatory, cardiovascular, and neurohormonal markers, to improve the accuracy of diagnosing and risk stratifying adverse events in post-myocardial infarction patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natriuretic proteins (BNP, NTproBNP) are used for diagnosis and risk stratification, then prognostic information is provided, but reliability in predicting high-risk patients is insufficient
Solution Approach 1:
The patent combines proADM with existing natriuretic proteins (BNP, NTproBNP) into a multimarker strategy. This merging of markers provides complementary information, where proADM adds independent predictive value for mortality and heart failure, thereby improving both reliability and measurement precision for risk stratification in post-MI patients
2Reliability
If proADM determination is added to the diagnostic panel, then independent predictive value is provided, but device complexity increases
Solution Approach 1:
The patent segments the diagnostic approach by introducing proADM as a distinct, independent marker that can be measured separately from natriuretic proteins. This segmentation allows each marker to provide specific, non-redundant information, improving predictive reliability while maintaining a structured, modular diagnostic framework that manages complexity
Data Source
AI summary
The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.